Promoting effects of Difrarel® on retinal function following panretinal photocoagulation in diabetic retinopathy

Authors: Zhang Moli,  Wei Wenbin,  Tian Bei
DOI: 10.3760/cma.j.cn115989-20210325-00205
Published 2022-03-10
Cite asChin J Exp Ophthalmol, 2022, 40(3): 247-252.

Abstract

Objective

To investigate the promoting effect of Difrarel® on retinal function following panretinal photocoagulation (PRP) in the eyes with diabetic retinopathy.

Methods

A non-randomized controlled study was performed.A total of 108 eyes of 108 patients with non-proliferative diabetic retinopathy (NPDR) were enrolled in Tongren Ophthalmology Center and Beijing Daxing District People’s Hospital from December 2014 to February 2020.The patients were divided into PRP group and PRP+ Difrarel® group according to different therapies under patients’ selection.Difrarel® was orally administered after PRP in 56 patients of PRP+ Difrarel® group, and only PRP was given in 52 patients of PRP group.The visual acuity, 30°~60° circular visual field and multifocal electroretinogram were examined before and 1 day, 1 month, 3 months, 6 months, 12 months after PRP.The central macular thickness (CMT) was measured by optical coherence tomography, and fundus neovascularization was observed by fluorescein fundus angiography at 6 and 12 months after PRP.The study protocol was approved by an Ethics Committee of Beijing Daxing District People’s Hospital (No.2021-F4).

Results

Visual improvement rate was 57.14% (32/56) and 32.69% (17/52) in PRP+ Difrarel® group and PRP group at the end of following-up, respectively, showing a significant difference between two groups (χ2=3.56, P<0.05). The visual field mean sensitivity was significantly different at different time points in two groups (Fgroup=4.77, P<0.05; Ftime=6.51, P<0.05), and was lower after PRP than those before treatment in both groups (both at P<0.05), and was significantly higher in PRP+ Difrarel® group than PRP group at 3, 6, 12 months after PRP (all at P<0.05). The P1 amplitude density in 3 to 5 rings in PRP+ Difrarel® group were higher than those in PRP group, and the differences were statistically significant (all at P<0.05). There was no significant difference in CMT between the two groups at different time points (Fgroup=3.57, P>0.05; Ftime=1.23, P>0.05). No new blood vessels and non-perfusion area were found in both groups.

Conclusions

Oral Difrarel® can improve retinal function after PRP in the eyes with NPDR.

Key words:

Diabetic retinopathy/therapy; Laser photocoagulation; Postoperative complications; Retina/physiological function; Anthocyanin

Contributor Information

Zhang Moli

Department of Ophthalmology, Beijing Daxing District People’s Hospital, Beijing 102600, China

Wei Wenbin

Beijing Tongren Eye Center, Beijing Key Laboratory of Intraocular Tumor Diagnosis and Treatment, Beijing Ophthalmology &

Visual Sciences Key Lab, Medical Artificial Intelligence Research and Verification Key Laboratory of the Ministry of Industry and Information Technology, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China

Tian Bei

Beijing Tongren Eye Center, Beijing Key Laboratory of Intraocular Tumor Diagnosis and Treatment, Beijing Ophthalmology &

Visual Sciences Key Lab, Medical Artificial Intelligence Research and Verification Key Laboratory of the Ministry of Industry and Information Technology, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China

(Read 29 times, 1 visits today)